Filing Details
- Accession Number:
- 0001447362-21-000227
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-29 16:07:39
- Reporting Period:
- 2021-09-27
- Accepted Time:
- 2021-09-29 16:07:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1447362 | Castle Biosciences Inc | CSTL | Services-Medical Laboratories (8071) | 770701774 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1856565 | M Kristen Oelschlager | C/O Castle Biosciences, Inc. 505 S Friendswood Drive, Suite 401 Friendswood TX 77546 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-09-27 | 8,574 | $70.94 | 98,966 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-09-27 | 1,426 | $71.52 | 97,540 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 25, 2021.
- This transaction was executed in multiple trades at prices ranging from $70.37 to $71.36, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Includes 423 shares acquired on August 31, 2021 under the Issuer's employee stock purchase plan.
- This transaction was executed in multiple trades at prices ranging from $71.37 to $72.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
